|Bid||90.21 x 900|
|Ask||90.60 x 1800|
|Day's Range||89.25 - 90.97|
|52 Week Range||74.13 - 147.17|
|PE Ratio (TTM)||25.13|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
In its Q2 2018 earnings conference call, Biogen (BIIB) updated its 2018 GAAP EPS guidance from the previously projected range of $22.20–$23.20 to $21.80–$22.40, which implies a YoY (year-over-year) rise of 83%–87%.
As discussed earlier, Allergan (AGN) reported a 2.9% rise in its YoY (year-over-year) revenue to $4.1 billion in the second quarter compared to $4.0 billion in the second quarter of 2017.
On July 25, Biogen (BIIB) and Eisai announced positive results from the Phase 2 study evaluating BAN2401, an investigational anti-amyloid-beta (or Aβ) protofibril antibody, in early Alzheimer’s disease (or AD) indication after 18 months of therapy. The patients also included those suffering from AD-related mild cognitive impairment as well as those with mild AD. The results from the Phase 2 trial seem to validate beta-amyloid as a potential target for treating Alzheimer’s disease.
A stock's price can fall for many reasons. The company may no longer be performing as it's expected to. The industry or sector could be temporarily out of fashion. Sometimes, a weak market simply pulls good stocks down with it. As long as the issue isn't fundamental (and long-term), you can still buy low and eventually sell high, even in a toppy market like today's. Today, we will look at 10 stocks with market caps between $10 billion and $200 billion that have fallen hard in the past year, but that some analysts think are poised for a bounce-back. These companies are in a variety of industries - everything from banking to pharmaceuticals to industrial products to consumer goods. Clearly, each of these stocks comes with some risk given the bearish drivers that have dragged them down by 20%, 30%, even 40%. But investors should be less concerned about why these stocks fell in the past, and more concerned about whether they realistically can rebound from here. None of these stocks need to reach their old highs for investors to neatly profit - the underlying companies just need to follow through on proposed ways to increase shareholder value. Here's a look at 10 battered stocks to buy for their recovery potential. SEE ALSO: 20 of the Best Stocks You Probably Haven't Heard Of
Futures Up on China-U.S. Trade Talks, China at New 52-Week Lows Washington sent an invitation to Beijing for trade talks in late August, and the Chinese have responded in kind. They plan to send their vice minister of commerce to discuss the situation, and U.S. futures are up on the news. Not so much for […] The post Market Morning: Gene Therapy Deregulation, Amazon to the Movies, SEC On Musk’s Tail appeared first on Market Exclusive.
In the first half of 2018, Bausch Health reported revenue of $4.1 billion compared to $4.3 billion in the same period last year. Bausch Health reported net income of -$873 million in the second quarter compared to -$38 million in the same period last year. In the first half of 2018, Bausch Health reported net income of -$3.45 billion compared to -$590 million in the same period last year.
After the first half of 2018, Bausch raised its full-year adjusted EBITDA guidance from $3.15 billion–$3.30 billion to $3.20 billion–$3.35 billion. In August, Bausch Health’s wholly owned subsidiary Salix Pharmaceuticals and US WorldMeds announced the launch of Lucemyra 0.18 mg tablets in the US market. Right now, Lucemyra is the first and only non-opioid drug indicated for the mitigation of opioid withdrawal symptoms for facilitating rapid opioid discontinuation in adults.
The Turkish Lira rout that started last week is the big story for this coming week. In turn, U.S. and European earnings seasons are winding down.
Alnylam Pharmaceuticals’ (ALNY) investigational RNAi therapeutic drug lumasiran is being developed for the treatment of primary hyperoxaluria type 1 (or PH1). Alnylam expects to initiate a Phase 3 trial of the drug in 2018, with its results expected in late 2019.
Corcept's (CORT) earnings and revenues lag estimates in Q2. Meanwhile, the company posts positive interim data from phase I/II study on its pipeline candidate relacorilant.
What a killer earnings result it was from Roku (NASDAQ:ROKU) and investors are having no reservations about bidding it up in response. Now rallying right into its prior high, keep an eye on Roku. Besting Roku on the day was Yelp (NASDAQ:YELP), which closed higher by nearly 30% vs Wednesday’s close.
Just because a stock has performed badly in the past, doesn't mean it's game over for the future. As investors, we can jump into stocks that are rising. But another strategy is to find poorly performing stocks on the cusp of rebounding. Obviously, this is a more risky approach. What happens if the poor results continue? Well, for instance, you can generate seriously lucrative returns. The key is to cherry-pick your stocks wisely by differentiating between stocks unfairly treated by the market, versus the stocks where all hope is truly lost. Luckily help is at hand. Here, I turned to top analyst ratings to pinpoint stocks that are worth a second look. I used TipRanks to focus on analysts with the sharpest stock picking abilities. These stocks have all posted losses, but the upside potential remains intact. Let's take a closer look at these rebounding stock picks now: SEE ALSO FROM KIPLINGER: 10 of the Market's Most Shorted Stocks
Crispr's stock has started to lose momentum after blasting higher earlier this year. Is the market correcting a prior mistake, or is this dip a buying opportunity?
As Tesla Inc (NASDAQ: TSLA ) explores an exit from the public markets, one Street analyst on Wednesday said Celgene Corporation (NASDAQ: CELG ) could pursue a similar path. The Rating RBC Capital analyst ...
Biotech giant Celgene could go private at 120 per share, an analyst suggested Wednesday after similarly sized electric-car maker Tesla confirmed it's discussing the possibility.
Elon Musk’s proposal to take Tesla Inc. private re-ignited one sell-side analyst’s thought that biotechnology giant Celgene Corp. may follow suit. RBC Capital Markets analyst Brian Abrahams revisited a concept he floated back in March that a leveraged buyout of the ailing drugmaker would enable it to capture value from its keystone cancer treatment, Revlimid, and take it out from under the microscope that is the public market. “It’s certainly a stretch to say the least,” said Bloomberg Intelligence analyst Asthika Goonewardene, noting he disagrees with the comparison of the two stocks.
As discussed earlier, Ionis Pharmaceuticals (IONS) reported year-over-year (or YoY) growth of 5% in revenues to $118 million during Q2 2018 as compared to revenues of $112 million during the second quarter of 2017. Ionis missed Wall Street analyst estimates for revenues and EPS in Q2 2018. Ionis reported commercial revenues of $57 million during Q2 2018, over 100% growth as compared to commercial revenues of $24 million during the second quarter of 2017.